Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease
R B Heuschkel, T T MacDonald, G Monteleone, M Bajaj-Elliott, J A Smith, S L Pender, R B Heuschkel, T T MacDonald, G Monteleone, M Bajaj-Elliott, J A Smith, S L Pender
Abstract
Background: Degradation of the extracellular matrix and ulceration of the mucosa are major features of inflammatory bowel disease (IBD). One of the most important enzymes in degrading the matrix and produced in excess by cytokine activated stromal cells, is stromelysin-1. The activity of stromelysin-1 is controlled by tissue inhibitor of metalloproteinase (TIMP-1), its natural inhibitor. In model systems excess stromelysin-1 produces mucosal degradation.
Methods: Quantitative competitive RT-PCR was used to analyse stromelysin-1 and TIMP-1 transcripts; western blotting was used to measure the amount of stromelysin-1 and TIMP-1 protein in biopsy samples from children with IBD.
Results: In biopsies from patients with active Crohn's disease (n=24), ulcerative colitis (n=23), and controls (n=16), TIMP-1 transcripts and protein were abundant and unchanged. Stromelysin-1 transcripts and protein were markedly elevated in mucosal biopsies obtained from inflamed sites of patients with active IBD but were not elevated in adjacent endoscopically normal mucosa (n=10). Elevated levels of stromelysin-1 transcripts in active Crohn's disease (n=5) returned to normal levels following treatment with enteral nutrition.
Conclusions: Stromelysin-1 is markedly overexpressed at inflamed sites in patients with IBD whereas TIMP-1 remains unaltered. Excess stromelysin-1 is likely to be responsible for loss of mucosal integrity in IBD.
Figures
References
- J Biol Chem. 1989 Oct 15;264(29):17374-8
- FASEB J. 1991 May;5(8):2145-54
- J Pediatr Gastroenterol Nutr. 1991 May;12(4):439-47
- Gastroenterology. 1992 Nov;103(5):1587-95
- Matrix Suppl. 1992;1:217-23
- J Immunol. 1993 Jun 15;150(12):5596-603
- J Gastroenterol Hepatol. 1993 Sep-Oct;8(5):437-41
- Gut. 1993 Dec;34(12):1705-9
- J Clin Pathol. 1994 Feb;47(2):113-6
- Cancer Res. 1994 Apr 15;54(8):2091-4
- FEBS Lett. 1994 Jul 25;349(1):45-9
- Cell Biol Int. 1994 Dec;18(12):1139-44
- Arthritis Rheum. 1995 Jul;38(7):969-75
- Aliment Pharmacol Ther. 1995 Oct;9(5):547-52
- Am J Pathol. 1996 Feb;148(2):519-26
- Biotechniques. 1996 Apr;20(4):670-4
- J Pediatr Gastroenterol Nutr. 1996 May;22(4):373-9
- Br J Dermatol. 1996 Jul;135(1):52-9
- Enzyme Protein. 1996;49(1-3):117-37
- Curr Eye Res. 1996 Oct;15(10):1060-8
- Gut. 1996 Aug;39(2):284-90
- FEBS Lett. 1997 Jan 20;401(2-3):213-7
- J Immunol. 1997 Feb 15;158(4):1582-90
- Am J Pathol. 1997 Feb;150(2):653-66
- Br J Rheumatol. 1997 Jun;36(6):643-50
- N Engl J Med. 1997 Oct 9;337(15):1029-35
- Gastroenterology. 1999 Nov;117(5):1069-77
- Biochem J. 1977 Jul 15;166(1):21-31
- Biochem Biophys Res Commun. 1985 Dec 17;133(2):483-90
- Gut. 1989 Jun;30(6):835-8
- Eur J Cell Biol. 1997 Oct;74(2):111-22
- Am J Pathol. 1998 Apr;152(4):1005-14
- J Immunol. 1998 Apr 15;160(8):4098-103
- Surgery. 1998 Aug;124(2):464-70
- Gastroenterology. 1998 Sep;115(3):573-83
- Ann N Y Acad Sci. 1998 Nov 17;859:237-40
- Gastroenterology. 1999 Oct;117(4):814-22
- J Hepatol. 1997 Sep;27(3):535-44
Source: PubMed